Generic MS Drug Development Was Protected, Sandoz Says

Law360, New York (April 18, 2013, 8:45 PM EDT) -- Sandoz Inc. asked a New York federal judge Wednesday to toss Teva Pharmaceuticals Industries Ltd.'s patent infringement suit, saying its use of a patented process as it developed a generic form of multiple sclerosis drug Copaxone was protected by the safe harbor exemption.

Teva sued Sandoz in December 2009 for using the polypeptide TP-116 in its preparation of generic glatiramer acetate — thereby allegedly infringing on four Teva patents — but Sandoz said Wednesday that it was allowed to use the chemical compound under the research...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.